Financial Health Assessment

Centaur Services Limited (Company No. 00787385)

Patient Profile

An important note before we begin: the record reviewed here contains the company's structural, compliance, and governance data, but the underlying balance sheet and profit & loss figures were not populated in this dataset. Think of this as a thorough physical examination where the blood test results are still pending — I can assess the patient's visible condition with confidence, but the internal lab work needs to be pulled before a complete diagnosis.

1. Financial Health Score: B+ (Provisional)

This is a strong structural score awarded on the basis of what can be verified. The company shows excellent "posture and reflexes" — six decades of continuous trading, immaculate filing discipline, and blue-chip parentage. The score is provisional because the quantitative evidence (profitability, liquidity, gearing) could not be examined. If the FY2025 accounts confirm healthy working capital and solvency, this score would likely move toward A- territory.

2. Key Vital Signs

Heart rate & blood pressure (compliance indicators): Normal and steady. - Accounts made up to 30 September 2025, with the next filing due 30 June 2027 — meaning the FY2025 accounts were filed on or ahead of schedule. Companies that file early almost always have healthy internal reporting cultures. - Confirmation statement current (made up to 10 October 2026, next due October 2027). - Zero overdue filings, zero penalties, no insolvency proceedings (not in liquidation, administration, or receivership).

Family medical history (ownership & support): Very strong. - The controlling shareholder, MWI Supply (UK Acquisition) Limited, connects this business to Cencora (formerly AmerisourceBergen), one of the world's largest pharmaceutical distribution groups. This is the corporate equivalent of a patient with a robust support network — access to group procurement scale, treasury facilities, and shared infrastructure. - The officer register confirms this integration: several directors are US-based, consistent with group-level executive appointments.

Longevity: Exceptional. - Incorporated in January 1964, this business has survived every major economic cycle of the past six decades — the 1970s stagflation, early-90s recession, 2008 financial crisis, and the pandemic era. Companies don't reach 61 without genuine resilience in the underlying business model.

Body mass (scale indicators): Substantial. - Share capital of £533,001 and a "Full" accounts filing category (rather than abbreviated small-company accounts) suggest a medium or larger entity. Small companies typically file reduced accounts; this one files the full set.

Symptoms requiring monitoring: Director turnover. - Two director resignations occurred in quick succession in mid-2026 (Xxxxxx Xxxxxxxxname shown to subscribers in June; Xxxxxx Xxxxxxxxname shown to subscribers in July). In a group-owned subsidiary, this pattern most often reflects routine group reorganisation rather than distress — these appear to be group appointees rotating. Still, any change in the attending physicians is worth noting.

3. Diagnosis

Structurally healthy; internal condition pending lab results.

What the examination reveals:

• No external symptoms of distress. No insolvency markers, no filing defaults, no disqualification records among the officer list. The company presents as an active, operating business with a live web presence.
• Deep group integration. The PSC structure and multinational board composition indicate this is a tightly-managed subsidiary within a global distribution group — a structure that typically provides financial shelter but also means key decisions are made at group level.
• A note on classification: the SIC code (75000, veterinary activities) suggests clinical practice, but the company's name, parentage, and profile are consistent with veterinary products distribution — a wholesale/supply business serving the animal health sector. This distinction matters for benchmarking, as distribution businesses carry different margin and working-capital profiles than practices do.
• The unknown: profitability, cash position, working capital, and debt levels cannot be verified from this record. Group backing is a powerful comfort factor, but a parent's strength is not a substitute for the subsidiary's own solvency — support arrangements must be confirmed, not assumed.

4. Prognosis

Favourable, with one condition attached.

A 61-year-old business with Fortune 500 parentage, spotless compliance behaviour, and continuous operation has, statistically, a very low likelihood of being in hidden distress. The veterinary supply sector benefits from structural demand (pet ownership and livestock health spending are resilient through economic cycles), though distribution businesses live on thin margins and disciplined working-capital management.

The mid-2026 director changes suggest some group restructuring is underway — most likely benign, but it flags the need to confirm the current accounts reflect any reorganisation of obligations or intercompany arrangements.

5. Recommendations (Treatment Plan)

1. Pull the lab results: Obtain the full accounts for the year ended 30 September 2025 from Companies House. Because the company files full accounts, the detail will be there. Examine net current assets (working capital), net assets, any going-concern language, and the auditor's opinion.
2. Check the register of charges: Group subsidiaries often carry intercompany loans or bank security. This reveals the true indebtedness picture that the PSC register cannot.
3. If extending credit, ask the parent guarantee question: Does MWI/Cencora stand behind this entity's obligations, or does it trade on its own balance sheet? This single fact changes the credit assessment materially.
4. Request interim management accounts for any significant commercial relationship — the September 2025 year-end figures are already over a year old.
5. Monitor new officer appointments following the mid-2026 departures; they will signal the direction of group reorganisation.

Names of the people mentioned are shown to subscribers. See subscription